Welcome to our dedicated page for Instil Bio SEC filings (Ticker: TIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Instil Bio, Inc. (TIL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, with its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody, in development for multiple solid tumors.
Instil Bio’s recent Form 8-K filings illustrate how the company uses current reports to communicate material information. Some 8-Ks reference results of operations and financial condition, where Instil furnishes press releases detailing quarterly financial results, operating expenses, and net losses. These filings often discuss research and development expenses, general and administrative expenses, restructuring and impairment charges, and the company’s use of non-GAAP financial measures such as non-GAAP net loss and non-GAAP net loss per share, which exclude non-cash stock-based compensation and restructuring and impairment charges.
Other 8-K filings focus on clinical and collaboration updates. For example, Instil Bio has filed an 8-K describing preliminary safety and efficacy data from ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s Phase 2 open-label, multicenter study of IMM2510/AXN-2510 in combination with chemotherapy for front-line advanced non-small cell lung cancer (NSCLC) in China. That filing summarizes partial response rates and safety observations, including the absence of dose-limiting toxicities and the nature of treatment-related adverse events.
Through these and other SEC filings, investors can review how Instil Bio reports its financial performance, presents reconciliations between GAAP and non-GAAP metrics, and discloses key developments related to AXN-2510 and its collaboration with ImmuneOnco. On Stock Titan, these documents are paired with AI-powered summaries that help explain the context and main points of each filing, making it easier to understand complex financial tables, clinical trial descriptions, and regulatory disclosures.